SAN DIEGO, Nov. 14, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the quarter ended S… […]
– Revenues reached a record $1.5 million, up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019- The number of commercial samples received increased 66% over the third quarter of 2018 and 12% over the second quarter of 2019-… […]
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ — Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the third quarter ended September 30, 2019.
“Following … […]
Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326Appointment of Cris Calsada as New Chief Financial Officer
LA JOLLA, Calif., Nov. 12, … […]
– Total Revenues Increase 81% to $46.2 million Compared to $25.6 million in Prior-year Period — First Quarter of Sustainable Profitability Expected in Second Quarter of 2020 — Board Authorizes Initiation of Capital Return with Share Repurchase Prog… […]
– Total Revenues Increase 81% to $46.2 million Compared to $25.6 million in Prior-year Period — First Quarter of Sustainable Profitability Expected in Second Quarter of 2020 — Board Authorizes Initiation of Capital Return with Share Repurchase Prog… […]
– Heron Raises Full-Year 2019 CINV Franchise Net Product Sales Guidance from $115-120 Million to $135 Million –
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on impr… […]
SAN DIEGO, Nov. 7, 2019 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including pr… […]
Company on Track for Amphora NDA Resubmission to the U.S. FDAPhase 2b AMPREVENCE Trial Results Anticipated in Q4 2019Management to Host Conference Call Thursday, November 7, 2019 at 11:00 a.m. EST
SAN DIEGO, Nov. 6, 2019 /PRNewswire/ — Evofem Biosci… […]
Conference call scheduled for 8:30 a.m. ET today- IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH- Clinical Development of VK0214 for X-ALD Expected to Begin 1H20- Balance Sheet Remains Strong with Approximately $290 Million… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
